Search company, investor...

Founded Year

2016

Stage

Series A - II | Alive

Total Raised

$47.1M

Last Raised

$9.58M | 3 yrs ago

About Enthera

Enthera is a biotech company whose mission is to develop new medical treatment for diabetes and intestinal disorders.

Headquarters Location

Via Gioberti 8

Milan, 20123,

Italy

+39 023456778

CB Insights
Looking for a leg up on competitive, customer and technology insights?
CB Insights puts confidence and clarity into your most strategic decisions.
See how. Join a demo.
Join a demo
Trusted by the world's smartest companies to:
  • Predict emerging trends
  • See competitors' playbooks
  • Stalk the smart money
  • Identify tomorrow's challengers
  • Spot growing industries
  • Kill analyst data work
Let's see how we can help you!
MicrosoftWalmartWells Fargo
You're one click away from the most comprehensive, unmatched analyst expertise in tech, in-depth private company data and a platform that brings it all together.
Click Now. Join a live demo
Join a demo

Enthera Patents

Enthera has filed 4 patents.

The 3 most popular patent topics include:

  • Immunology
  • Immune system
  • Monoclonal antibodies
patents chart

Application Date

Grant Date

Title

Related Topics

Status

10/2/2019

Transcription factors, Human proteins, Immunology, Growth factors, Peptides

Application

Application Date

10/2/2019

Grant Date

Title

Related Topics

Transcription factors, Human proteins, Immunology, Growth factors, Peptides

Status

Application

Latest Enthera News

Enthera Pharmaceuticals Initiates Phase 1 Clinical Trial with Lead Candidate Ent001

Mar 7, 2023

MILAN--(BUSINESS WIRE)--Enthera Pharmaceuticals (“Enthera”), a biotech company developing first-in-class biologics for selected autoimmune conditions, today announces the start of a Phase 1 first-in-human (FIH) clinical trial with its lead candidate Ent001. Ent001 is a monoclonal antibody (mAb) targeting the IGFBP3/TMEM219 pathway, which plays a critical role in both inflammatory bowel disease (IBD) and type 1 diabetes (T1D). Elevated levels of IGFBP3 bind to the TMEM219 receptor, causing apopt

Enthera Frequently Asked Questions (FAQ)

  • When was Enthera founded?

    Enthera was founded in 2016.

  • Where is Enthera's headquarters?

    Enthera's headquarters is located at Via Gioberti 8, Milan.

  • What is Enthera's latest funding round?

    Enthera's latest funding round is Series A - II.

  • How much did Enthera raise?

    Enthera raised a total of $47.1M.

  • Who are the investors of Enthera?

    Investors of Enthera include Roche Venture Fund, Sofinnova Partners, JDRF T1D Fund, Banca Profilo, Banor Sim and 5 more.

CB Insights
Looking for a leg up on competitive, customer and technology insights?
CB Insights puts confidence and clarity into your most strategic decisions.
See how. Join a demo.
Join a demo
Trusted by the world's smartest companies to:
  • Predict emerging trends
  • See competitors' playbooks
  • Stalk the smart money
  • Identify tomorrow's challengers
  • Spot growing industries
  • Kill analyst data work
Let's see how we can help you!
MicrosoftWalmartWells Fargo

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Join a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.